 |
|
Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A
Reza Asari, MD;
Christian Scheuba, MD;
Klaus Kaczirek, MD;
Bruno Niederle, MD
Arch Surg. 2006;141:1199-1205.
Hypothesis Adrenal-sparing adrenalectomy is considered the treatment of choice for hereditary bilateral pheochromocytoma in patients with multiple endocrine neoplasia type 2A (MEN 2A).
Design Retrospective analysis of prospectively documented data with a mean ± SD follow-up of 81.5 ± 85.3 months. The PubMed database was searched for articles published between 1975 and 2004 to identify published series and/or case reports.
Setting University hospital referral center.
Patients In 17 (22%) of 77 patients with various mutations of the RET proto-oncogene, unilateral (n = 12) or bilateral (n = 5) pheochromocytomas were documented at the time of diagnosis or during the course of MEN 2A. Adrenal-sparing surgery was performed in 13 patients (group 1), synchronous bilateral total adrenalectomy in 4 patients (group 2A), and metachronous bilateral total adrenalectomy in 5 patients after adrenal-sparing adrenalectomy (group 2B).
Main Outcome Measures Measurement of 24-hour urinary catecholamine levels (noradrenaline, adrenaline, and dopamine) and, in case of high catecholamine levels, imaging studies to localize the tumors in 1 or both adrenal glands to determine the size and exclude extra-adrenal tumors and distant metastasis.
Results The mean±SD estimated 5- and 10-year cumulative risk of developing recurrence in both groups was 38.5% ± 15.7%. Five (38%) of 13 patients in group 1 developed recurrence in the contralateral gland. Two (22%) of 9 patients in groups 2A and 2B developed several episodes of an addisonian crisis, 1 of whom died.
Conclusions Substantial morbidity and mortality are associated with addisonian crisis after bilateral adrenalectomy. Adrenal-sparing adrenalectomy and close monitoring of the remnant may be the treatment of choice for hereditary bilateral pheochromocytoma in MEN 2A, since overall recurrence is low.
Author Affiliations: Division of General Surgery, Section of Endocrine Surgery (Drs Asari, Scheuba, and Kaczirek), and Department of Surgery (Dr Niederle), Medical University of Vienna, Vienna, Austria.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A—Invited Critique
Quan-Yang Duh
Arch Surg. 2006;141(12):1205.
EXTRACT
| FULL TEXT
|
